MilliporeSigma Invests €35 Million to Strengthen Biosafety Testing in Scotland
Under the €35 million (US$37 million) investment, MilliporeSigma will expand its sites in Glasgow and Stirling, Scotland, to increase biosafety testing for drug development and commercialization.
MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced a €35 million (US$37 million) investment on May 31, 2023 made by its life science business sector into the company’s Glasgow and Stirling sites in Scotland. The investment is intended to increase biosafety testing for drug development and commercialization at those sites.
The investment includes a new 1200-m2 facility in Glasgow that will house molecular biology and sequencing services, and the company will add biosafety testing, analytical development, and viral clearance suites in its current buildings to expand testing capacity. In addition, the expansion will create nearly 500 new jobs, raising the company’s workforce to more than 1200 employees across the two sites.
“We remain committed to ensuring the safety of the world's medicines through our state-of-the-art testing solutions for our customers around the world that drive new treatments,” said Dirk Lange, head of Life Science Services, MilliporeSigma, in a company press release. “Since mid-2022, we have announced investments of more than €350 million [US$374 million] in our global testing network to meet the growing demand for these services.”
Source: MilliporeSigma
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
